Borean Pharma Founder Receives Prize of 50 000 DKK

Borean Pharma ApS has announced that Associate Professor Hans Christian Thogersen, the founder and CSO of Borean, has received a prize from Science Park Aarhus in recognition of Borean’s success as a company.

To commemorate the 20th anniversary of the foundation of Aarhus Science Park in 2006, it will grant an award of 100 000 DKK (13000 Euro) annually to the person, company or institute that made a strong effort to link commerce and science.

Professor Thiogersen is one of two individuals who won this inaugural prize. The award reflects the formidable achievement in launching Borean Pharma based on studies of the C-Type lectin, Tetranectin performed by him, the co-founder Michael Etzerodt, and Thor Las Holtet.

Hans Christian Thogersen first came to Science Park Aarhus in 1989 as a lecturer in the Institute of Molecular Biology.

His research over the next decade led to the breakthroughs in protein engineering that formed the basis of Borean Pharma, which he and Michael Etzerodt founded in 2001.

Since then Borean Pharma has used this technology to discover and develop engineered protein therapeutics and recently announced an eye-catching deal with Roche over the licensing of Borean’s lead product, Apo-AI, a protein for the treatment of atherosclerosis.

"I am delighted to have won this award," commented Hans Christian Thogersen "I am proud of what we have achieved at Aarhus University and Borean Pharma and pleased that it has been recognised."